Sensei Biotherapeutics Inc(SNSE) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Full metrics table
| Index | - | P/E | - | EPS (ttm) | -19.16 | Insider Own | 81.63% | Shs Outstand | 1.3M | Perf Week | -11.26% |
| Market Cap | 0.02B | Forward P/E | - | EPS next Y | 91.78% | Insider Trans | -2.33% | Shs Float | 0.3M | Perf Month | -38.33% |
| Enterprise Value | -0.01B | PEG | - | EPS next Q | -5.04 | Inst Own | 99.47% | Short Float | 319.31% | Perf Quarter | -59.73% |
| Income | -0.02B | P/S | - | EPS this Y | -508.07% | Inst Trans | 98.39% | Short Ratio | 15.16 | Perf Half Y | 51.69% |
| Sales | 0.00B | P/B | 0.71 | EPS next 5Y | 26.41% | ROA | -59.72% | Short Interest | 0.80M | Perf YTD | 21.84% |
| Book/sh | 18.24 | P/C | 0.7 | EPS past 3/5Y | 19.15% -4.83% | ROE | -70.19% | 52W High | -64.64% ($36.76) | Perf Year | 93.74% |
| Cash/sh | 18.66 | P/FCF | - | Sales past 3/5Y | - | ROIC | -104.26% | 52W Low | 132.14% ($5.60) | Perf 3Y | -52.55% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | 19.36% | Gross Margin | - | Volatility(W/M) | 18.18% 15.65% | Perf 5Y | -94.58% |
| Dividend TTM | - | EV/Sales | - | Sales Y/Y TTM | - | Oper. Margin | - | ATR (14) | 2.63 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 5.81 | EPS Q/Q | 37.2% | Profit Margin | - | RSI (14) | 35.6 | Recom | 1 |
| Dividend Gr. 3/5Y | - | Current Ratio | 5.81 | Sales Q/Q | - | SMA20 | -20.17% ($16.28) | Beta | -0.09 | Target Price | $51.67 |
| Payout | - | Debt/Eq | 0.09 | Earnings | 2026/5/15 | SMA50 | -44.39% ($23.38) | Rel Volume | 1.1 | Prev Close | $10.79 |
| Employees | 29 | LT Debt/Eq | 0.01 | EPS/Sales Surpr. | -21101.61% - | SMA200 | -20.02% ($16.25) | Avg Volume(3M) | 0.05M | Price | $13 |
| IPO | 2021/2/4 | Option/Short | No/Yes | Trades | 612 | Volume | 57,917 | Change | 20.48% |
🧬 This is a clinical-stage biotech developing next-generation immuno-oncology drugs designed to block the mechanisms cancer cells use to evade the immune system. Its lead candidate, solnerstotug (SNS-101), is an antibody targeting the VISTA checkpoint, currently in Phase 1/2 clinical trials for solid tumors. The company is still in the research and development stage with no revenue to date.
Over the past 1 year, on the lower side
65% below its 1-year high.
Traded about as much as usual. That is 110% of its average volume.
SNSE has a sound balance sheet but weak earning power
Losses or thin margins. Early-stage growth or weakening competitiveness
Tap to view numbers
Growth has stalled
Earnings are expected to grow by -508.1% this year.
Tap to view numbers
Not enough quarters to judge yet
Only 2 quarter(s) reported, so no grade yet.
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -94.6%. The S&P 500 did +65% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Short interest is a burden
319.3% of the float is sold short.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
It ranks #470 of 598 in the industry
Based on market cap of $17M.
MCRB#469 Seres Therapeutics Inc $18M PER - SNSE#470 Sensei Biotherapeutics Inc $17M PER - 
CNTX#470 Context Therapeutics Inc $17M PER - 
JSPR#471 Jasper Therapeutics Inc $17M PER - 
RADX#472 Radiopharm Theranostics Ltd ADR $17M PER - 
FAQ
What kind of company is SNSE?
SNSE belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of SNSE?
The market cap of SNSE is approximately $17M, ranking 5,346 within its sector.
What is the 52-week high and low for SNSE?
SNSE has recorded a 52-week high of $36.76 and a low of $5.60.
